IASLC WCLC 2021: Exploratory Analysis of IMpower010 Shows Benefits of Atezolizumab Across a Wide Variety of Non–Small Cell Lung Cancer Patients
Benefits were observed in most subgroups of patients with stage II to IIIA disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.